GET THE APP

2,7- Phloroglucinol-6,6-bieckol protects INS-1 pancreatic β cells against high glucose-induced apoptosis
..

Pharmaceutical Regulatory Affairs: Open Access

ISSN: 2167-7689

Open Access

2,7- Phloroglucinol-6,6-bieckol protects INS-1 pancreatic β cells against high glucose-induced apoptosis


9th Annual European Pharma Congress

June 26-28, 2017 Madrid, Spain

Ji Sook Han, Hyun Ah Lee and Ji Hyeok Lee

Pusan National University, Republic of Korea
Lee Gil Ya Cancer and Diabetes Institute, Republic of Korea

Posters & Accepted Abstracts: Pharmaceut Reg Affairs

Abstract :

Background: Impaired function and decreasing numbers of pancreatic ?² cells are key factors in development of type 2 diabetes. Aim: The aim of this study is to investigate whether 2,7"-phloroglucinol-6,6'-bieckol protects INS-1 pancreatic ?² cells against high glucose-induced glucotoxicity and apoptosis. Results: High-glucose (30 mM) treatment led to glucotoxicity and induced apoptosis in INS-1 pancreatic ?² cells. But treatment with 10~50 ?¼M of 2,7"-phloroglucinol-6,6'-bieckol significantly alleviated the glucotoxicity and increased the cell viability. The treatment with 2,7"-phloroglucinol-6,6'-bieckol decreased dose dependently intracellular reactive oxygen species, lipid peroxidation, and nitric oxide levels increased by high glucose treatment. Furthermore, 2,7"-phloroglucinol-6,6'-bieckol significantly reduced pro-apoptotic Bax, caspase 9, and caspase 3 expressions, whereas it increased anti-apoptotic Bcl-2 and PARP expressions. When the type of cell death was identified using annexin V/propidium iodide staining, 2,7"-phloroglucinol-6,6'-bieckol significantly decreased the numbers of early apoptotic and late apoptotic cells induced by high glucose. Conclusion: These results suggest that 2,7"-phloroglucinol-6,6'-bieckol might be useful as a potential pharmaceutical agent to protect the pancreatic ?² cells against high glucose-induced apoptosis.

Biography :

Ji Sook Han is a Professor and is doing research on developing a bioactive compound from natural plants, especially seaweeds, and investigating its effect for the prevention and treatment of obesity and type 2 diabetes. The active compound containing in seaweeds may be a good anti-diabetic source by improving insulin secretary defect or insulin resistance. It may also be a potential anti-obesity source owing to its inhibitory effect on adipogenesis. She evaluates the effect and mechanism of a bioactive compound isolated from natural plant through in vitro and in vivo study.

Email: hanjs@pusan.ac.kr

Google Scholar citation report
Citations: 533

Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report

Pharmaceutical Regulatory Affairs: Open Access peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward